Galmed Pharmaceuticals Ltd is a biotechnology business based in the US. Galmed Pharmaceuticals shares (GLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Galmed Pharmaceuticals employs 18 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $1.52 |
|---|---|
| 52-week range | $1.31 - $6.25 |
| 50-day moving average | $2.16 |
| 200-day moving average | $2.71 |
| Wall St. target price | $17.60 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.49 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.52 from 2022-01-25
| 1 week (2022-01-19) | -5.30% |
|---|---|
| 1 month (2021-12-23) | -25.12% |
| 3 months (2021-10-26) | -38.21% |
| 6 months (2021-07-26) | -41.09% |
| 1 year (2021-01-26) | -59.52% |
|---|---|
| 2 years (2020-01-24) | -73.66% |
| 3 years (2019-01-25) | 7.64 |
| 5 years (2017-01-26) | 3.95 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -42.84% |
| Return on equity TTM | -77.28% |
| Profit margin | 0% |
| Book value | $1.50 |
| Market capitalisation | $38.1 million |
TTM: trailing 12 months
We're not expecting Galmed Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Galmed Pharmaceuticals's shares have ranged in value from as little as $1.311 up to $6.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galmed Pharmaceuticals's is 1.9863. This would suggest that Galmed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.